

Düsseldorf, June 2nd, 2022. Oligomers count. Two manuscripts published in high-ranked journals.

attyloid GmbH is pleased to announce that two recent manuscripts have been published in *npj Parkinson's Disease*, one of the prestigious journals of the Nature Portfolio, and *Cell Reports Medicine*. Both publications demonstrate the feasibility and utility of attyloid's sFIDA technology as a quantitative and ultra-sensitive approach to beta-Amyloid, alpha-Synuclein and Tau oligomers as biomarkers of Alzheimer's, Parkinson's and other CNS diseases. The now-published data demonstrate the value of sFIDA as a highly expedient technology for de-risking pre-clinical and clinical studies of the growing number of drug candidates targeting the toxic oligomers. According to Prof Dieter Willbold, chair of attyloid's supervisory board, "These oligomers are extremely useful biomarkers that perfectly match the mechanism of action of anti-prionic compounds. And attyloid's sFIDA technology reliably measures these biomarkers in body liquids." Dr Oliver Bannach, CEO of attyloid, emphasizes "It is not only about identifying those patients that will most likely respond to the treatment, but also determining target engagement and therapeutic success at the molecular level."

Blömeke, L. et al., "Quantitative Detection of α -Synuclein and Tau Oligomers and other Aggregates by Digital Single Particle Counting", *npj Parkinsons Dis.*, 8, 68.
<https://doi.org/10.1038/s41531-022-00330-x> (2022).

B. Kass et al., "A β oligomer concentration in mouse and human brain and its drug induced reduction ex vivo." *Cell Reports Medicine*, 3, 100630 <https://doi.org/10.1016/j.xcrm.2022.100630> (2022)

About attyloid:

attyloid is a biotech company built on strong scientific expertise in the field of protein misfolding and aggregation. Through licensing partnerships, attyloid has been granting access to its proprietary sFIDA technology primarily as biomarker assay for CNS disease-relevant oligomeric target proteins such as Tau, alpha-Synuclein, beta-Amyloid, thereby de-risking its licensees' respective therapeutic candidates over the course of the whole course of pre-clinical and clinical R&D.

Contact: info@attyloid.com